Selection And Bioactivity Detection Of CD28 Antagonistic Peptoids, CD137 Binding Peptides

ObjectiveThe CD28-B7 pathway has been described as one of the best characterized, critical costimulatory pathway for T cell activation, so it may serve as a potential target for blocking T cell activation and thereby treating autoimmune diseases and ameliorating transplantation rejection.The most common agent to block CD28-B7 costimulatory pathway is specific monoclonal antibodsy, such as anti-CD80/CD86mAbs. But monoclonal antibodies are mouse derived and have many side-effects in application. Otherwise, the production of humanized mAb is not only difficult but also expensive, so its application is limited. It is very necessary to make out more effective and cheaper blocking agents to block the costimulatory pathway.Peptoid, oligomers of N-substituted glycines, is a new kind of blocking agent. It can interact with receptor or enzyme, so can be used as a small compound substitute for peptide to block the reaction of receptor with its natural ligand. Peptoid can be designed based on the receptor's conformation and synthesized by combinatory chemistry. Nowadays, peptoids attract more and more attention for their broad variety of biological activities and proteolytic stability.The object of this research is to select peptoids that can block CD28-B7 pathway...